Search results for "Systemic mycosis"

showing 3 items of 3 documents

In vitro activity of fluconazole, voriconazole and caspofungin against clinical yeast isolates.

2007

Predicting the clinical outcome of a systemic mycosis is often a difficult task, especially when microbiological resistance is one of the factors contributing to therapeutic failure. Some of these factors are host-related--e.g. immune state, site and severity of infection, poor compliance to therapy--while others are associated with the drug's characteristics--e.g. dosage, type of compound (fungistatic/fungicidal), pharmacokinetic properties and drug-drug interactions. In the last few years, clinicians have been confronted with the problem of selecting the most appropriate antifungal therapy for systemic infections and have highlighted the need for a reliable method to assay the in vitro su…

DrugAntifungal AgentsSystemic mycosismedia_common.quotation_subjectMicrobial Sensitivity TestsBiologyPharmacologyPeptides Cyclicchemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginDrug Resistance FungalmedicineHumansPharmacology (medical)Fluconazolemedia_commonCandidaPharmacologyVoriconazoleTriazolesYeastIn vitroInfectious DiseasesPyrimidinesOncologychemistryVoriconazoleCaspofunginFluconazolemedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Associations of Antifungal Treatments With Prevention of Fungal Infection in Critically Ill Patients Without Neutropenia

2017

BACKGROUND: Invasive fungal infections are important causes of morbidity and mortality among critically ill patients. Early institution of antifungal therapy is pivotal for mortality reduction. Starting a targeted antifungal therapy after culture positivity and fungi identification requires a long time. Therefore, alternative strategies (globally defined as 'untargeted antifungal treatments') for antifungal therapy institution in patients without proven microbiological evidence of fungal infections have been discussed by international guidelines. This review was originally published in 2006 and updated in 2016. This updated review provides additional evidence for the clinician dealing with …

Medicine General & Introductory Medical Sciences0301 basic medicineAntifungalmedicine.medical_specialtyAntifungal AgentsNeutropeniaSystemic mycosismedicine.drug_classCritical Illness030106 microbiologyMycoseNeutropeniaPlacebo03 medical and health sciences0302 clinical medicinemedicineAntifungal AgentHumansInvasive Fungal InfectionMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness.industryCritically illMedicine (all)030208 emergency & critical care medicineGeneral Medicinemedicine.diseaseMycosesClinical questionCritical illnessCritical IllnebusinessInvasive Fungal InfectionsHumanJAMA
researchProduct

Retinal microglia are activated by systemic fungal infection

2014

Purpose: To determine whether systemic fungal infection could cause activation of retinal microglia and therefore could be potentially harmful for patients with retinal degenerative diseases. Methods: Activation of retinal microglia was measured in a model of sublethal invasive candidiasis in C57BL/6J mice by (i) confocal immunofluorescence and (ii) flow cytometry analysis, using anti-CD11b, anti-Iba1, anti-MHCII and anti-CD45 antibodies. Results: Systemic fungal infection causes activation of retinal microglia, with phenotypic changes in morphology, surface markers expression, and microglial re-location in retinal layers. Conclusions: As an excessive or prolonged microglial activation may …

Retinal Ganglion CellsSystemic mycosisFarmacologíaBiología CelularAxonal TransportRetinachemistry.chemical_compoundMicemedicineAnimalsMicroglial activationInflammationMicroscopy ConfocalMicrogliabusiness.industryRetinal DegenerationCandidiasisRetinalFlow CytometryImmunohistochemistryMice Inbred C57BLDisease Models Animalmedicine.anatomical_structurechemistryImmunologyChristian ministryFemaleMicrogliabusinessInfection
researchProduct